Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies June 30, 2026
Independent DMC recommended continuation of Ph 3 OVATION 3 trial of IMNN-001 + SOC neoadjuvant and adjuvant chemo in 1L ovarian cancer June 30, 2026
VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Ph 1/2 Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors June 30, 2026
FDA Approves KEYTRUDA and KEYTRUDA QLEX each with Trodelvy as 1L Treatment of PD-L1+ (CPS ≥10) Advanced TNBC June 30, 2026
First patient dosed in RASolute 305 Ph 3 Trial of Zoldonrasib-Chemo combo in 1L RAS G12D Metastatic Pancreatic Cancer June 30, 2026
FAILED TRIAL: Ph 3 SigVie-002/Be6A Lung-01 trial of sigvotatug vedotin in 2L+ NSCLC did not show a statistically significant OS improvement vs docetaxel June 30, 2026
Datroway recommended for approval in the EU by CHMP for patients with 1L metastatic TNBC who are not candidates for immunotherapy June 30, 2026
Enhertu approved in the EU for patients with previously treated HER2+ve metastatic solid tumours June 30, 2026
Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from CIRM to Support Clinical Development of SRN-101 in High-Grade Glioma June 30, 2026
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Ph 3 Registrational Trial of APG-157 in Head and Neck Cancer June 30, 2026
Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib June 30, 2026
First Patient enrolled in Ph 1/2 Trial Evaluating PM54 Plus Pembrolizumab in Advanced Solid Tumors June 30, 2026
Strategic Reorganization to Support ZYNLONTA Growth Opportunities and Regulatory Priorities Announced June 30, 2026
Positive Ph 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma Announced June 30, 2026
FAILED TRIAL: Ph 2 DOVACC study evaluating UV1 in BRCAwt platinum sensitive recurrent ovarian cancer did not meet primary endpoint of PFS improvement June 30, 2026
BfArM Approval to Initiate Ph 2/3 Trial of SIL204 in Locally Advanced Pancreatic Cancer June 30, 2026
CHMP recommendation advances TECVAYLI (teclistamab) plus daratumumab as a potential standard of care for RRMM June 30, 2026
NMPA approves satricabtagene autoleucel for treating 3L+ Claudin18.2+ve, HER2-neg advanced G/GEJA June 30, 2026
